QuadMedicine Inc.
KKRX:4644904,070.00
KRW
-330.00
(-7.50%)
ISIN
KR7464490002
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Seung-Gi Baek
- Full Time Employees
- 90
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seongnam-si South Korea
- Website
- quadmedicine.com
- Similar Companies
- Business
- QuadMedicine Inc. is a South Korea-based biotechnology and medical device company primarily engaged in the development, manufacturing, and commercialization of innovative microneedle drug delivery systems (DDS) and medical aesthetic solutions. The company operates through three core business segments: Pharmaceutical Delivery Systems, Cosmeceuticals and Medical Aesthetics, and Contract Development and Manufacturing Organization (CDMO) Services. Its product and service portfolio includes soluble, coated, and separable microneedle array patches for transdermal delivery of vaccines, biopharmaceuticals, and synthetic therapeutics; medical patches targeting indications including infectious diseases, osteoporosis, metabolic disorders, and local anesthesia; high-performance cosmeceutical microneedle patches for anti-aging, wrinkle improvement, skin brightening, and targeted blemish care; specialized formulation design and micro-encapsulation technologies for active pharmaceutical ingredients; and turnkey CDMO services encompassing automated aseptic mass-production, process validation, clinical trial batch manufacturing, and regulatory filing support for global healthcare partners. Founded in 2017, QuadMedicine Inc. is headquartered in Seongnam-si, Gyeonggi-do, South Korea, and delivers products and technological solutions to pharmaceutical, aesthetic, and biotechnology clients across domestic and international markets. In recent developments, the company completed its public listing on the KONEX market of the Korea Exchange (KRX: 464490) to secure capital for clinical pipeline expansion and support its planned technology-special transfer to the KOSDAQ market. QuadMedicine has advanced strategic research partnerships and grant-backed development programs with international organizations, including the International Vaccine Institute (IVI) and the RIGHT Foundation, to co-develop thermostable, painless microneedle vaccine delivery platforms. Furthermore, the company has expanded its automated cGMP-ready manufacturing facilities to increase production throughput, broaden its commercial CDMO client partnerships, and accelerate pre-clinical and clinical evaluation of its proprietary separable microneedle therapeutics.